Research Information System
2nd KOCAELİ SCIENCE CONGRESS (KOSC-2025) , Kocaeli, Turkey, 19 November - 21 December 2025, pp.119, (Summary Text)
This study evaluates the anticancer potential of the GLP-1 receptor agonist liraglutide in estrogen positive (MCF-7) and estrogen-negative (MDA-MB-231) breast cancer cell lines, focusing on its interaction with the DR5 (Death Receptor 5) apoptotic pathway. Cell viability analysis demonstrated that liraglutide significantly reduced proliferation after 72 hours of treatment, yielding IC₅₀ values of 3400 nM for MDA-MB-231 and 4800 nM for MCF-7 cells. Flow cytometric assessment revealed a marked increase in early and late apoptotic populations, together with elevated DR5 expression following treatment. Protein expression analysis confirmed the upregulation of DR5 and p53, supporting the activation of apoptotic signaling mechanisms.Collectively, these findings demonstrate that liraglutide inhibits breast cancer cell growth and induces apoptosis through DR5-dependent signaling, suggesting its potential as a promising therapeutic candidate for breast cancer treatment. Further preclinical validation is warranted to clarify its efficacy and safety in translational applications.